Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Gorilla Technology
GRRR
US Stock MarketDetailed Quotes
ELVN Enliven Therapeutics
- 20.690
- +0.420+2.07%
Close Mar 11 16:00 ET
- 20.690
- 0.0000.00%
Post 16:05 ET
1.01BMarket Cap-11.48P/E (TTM)
20.750High19.500Low212.91KVolume20.420Open20.270Pre Close4.32MTurnover0.80%Turnover RatioLossP/E (Static)48.86MShares30.03052wk High3.50P/B547.65MFloat Cap11.67052wk Low--Dividend TTM26.47MShs Float250.840Historical High--Div YieldTTM6.17%Amplitude3.896Historical Low20.300Avg Price1Lot Size
Enliven Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 23.29%-12.19M | -69.60%-20.44M | -12.08%-23.36M | -91.01%-61.27M | -53.25%-12.48M | -146.53%-15.89M | -69.13%-12.05M | -101.18%-20.84M | -67.64%-32.08M | -23.52%-8.15M |
| Net income from continuing operations | -11.49%-23.16M | -19.31%-19.95M | -54.43%-22.74M | -90.07%-71.58M | -102.83%-19.37M | -96.79%-20.77M | -88.11%-16.72M | -69.85%-14.72M | -52.23%-37.66M | -13.80%-9.55M |
| Depreciation and amortization | 2.56%80K | 5.41%78K | 17.91%79K | 38.14%297K | 21.88%78K | 30.00%78K | 42.31%74K | 71.79%67K | 86.96%215K | 93.94%64K |
| Other non cash items | --7K | ---720K | --79K | --306K | --78K | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 58.25%4.99M | -455.27%-4.38M | 45.14%-4.64M | 219.86%1.4M | 801.65%5.46M | 161.58%3.15M | 21.94%1.23M | -254.26%-8.45M | -87.72%438K | -47.21%606K |
| -Change in prepaid assets | 132.34%783K | -850.00%-2.45M | 40.18%-3.64M | -132.89%-3.7M | 2,365.79%1.72M | 162.18%337K | 175.81%326K | -1,023.25%-6.09M | -182.42%-1.59M | 82.49%-76K |
| -Change in payables and accrued expense | 40.90%4.29M | -304.18%-1.86M | 61.44%-910K | 167.49%5.41M | 461.09%3.82M | 74.44%3.04M | -36.92%909K | -28.05%-2.36M | -49.36%2.02M | -55.95%681K |
| -Change in other current liabilities | 63.32%-84K | -8,200.00%-83K | -8,200.00%-83K | -7,850.00%-310K | -8,000.00%-79K | ---229K | ---1K | ---1K | --4K | --1K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 23.29%-12.19M | -69.60%-20.44M | -12.08%-23.36M | -91.01%-61.27M | -53.25%-12.48M | -146.53%-15.89M | -69.13%-12.05M | -101.18%-20.84M | -67.64%-32.08M | -23.52%-8.15M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 141.71%14.83M | 77.78%-33.67M | -57,593.55%-17.89M | -24,150.33%-148.41M | 38,402.97%38.69M | -253,821.43%-35.55M | -49,905.94%-151.52M | 84.02%-31K | -220.42%-612K | -77.19%-101K |
| Net PPE purchase and sale | -37.50%-22K | 97.73%-2K | 35.48%-20K | 75.65%-149K | 86.14%-14K | -14.29%-16K | 70.96%-88K | 84.02%-31K | -220.42%-612K | -77.19%-101K |
| Net investment purchase and sale | 167.47%23.98M | 71.17%-43.66M | ---17.87M | ---148.26M | --38.7M | ---35.53M | ---151.43M | --0 | --0 | --0 |
| Net other investing changes | ---9.13M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 141.71%14.83M | 77.78%-33.67M | -57,593.55%-17.89M | -24,150.33%-148.41M | 38,402.97%38.69M | -253,821.43%-35.55M | -49,905.94%-151.52M | 84.02%-31K | -220.42%-612K | -77.19%-101K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 362.82%1.12M | 164.04%1.81M | -61.98%90.27M | 13,123.12%234.29M | 103.79%90K | -359.15%-425K | -56,500.00%-2.82M | 57,954.03%237.44M | -77.07%-1.8M | -60.93%-2.38M |
| Net common stock issuance | --0 | ---305K | --90M | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | 3,889.29%1.12M | 1,397.16%2.11M | 92.86%270K | -32.49%399K | 592.31%90K | --28K | 2,720.00%141K | -75.57%140K | --591K | --13K |
| Net other financing activities | ---- | ---- | ---- | 9,886.07%233.89M | --0 | ---453K | ---2.96M | 144,795.73%237.3M | -61.49%-2.39M | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 362.82%1.12M | 164.04%1.81M | -61.98%90.27M | 13,123.12%234.29M | 103.79%90K | -359.15%-425K | -56,500.00%-2.82M | 57,954.03%237.44M | -77.07%-1.8M | -60.93%-2.38M |
| Net cash flow | ||||||||||
| Beginning cash position | -22.93%96.93M | -48.92%149.22M | 32.55%100.2M | -31.33%75.59M | -14.28%73.9M | 35.95%125.77M | 192.35%292.16M | -31.33%75.59M | -15.60%110.08M | -27.07%86.21M |
| Current changes in cash | 107.23%3.75M | 68.57%-52.29M | -77.36%49.02M | 171.34%24.61M | 347.52%26.29M | -723.69%-51.87M | -2,141.81%-166.39M | 2,234.50%216.57M | -69.55%-34.49M | -30.70%-10.62M |
| End cash Position | 36.23%100.68M | -22.93%96.93M | -48.92%149.22M | 32.55%100.2M | 32.55%100.2M | -14.28%73.9M | 35.95%125.77M | 192.35%292.16M | -31.33%75.59M | -31.33%75.59M |
| Free cash flow | 23.22%-12.22M | -68.39%-20.44M | -12.00%-23.38M | -87.89%-61.42M | -51.54%-12.5M | -146.25%-15.91M | -63.42%-12.14M | -97.77%-20.88M | -69.15%-32.69M | -23.98%-8.25M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |